underlying causes and possible curative treatments is a fundamental role for oncologists, it is not true that they are 'just interested in finding a cure for cancer; a foolhardy and costly exercise which diverts them and resources from more cost effective areas'. Indeed more than half of their work load is concerned with the relief of symptoms by radiotherapy and/ or chemotherapy. Neither are palliative care physicians motivated only by a wish to help their patients die comfortably! The term continuing care is sometimes used to encompass the multidisciplinary aspects of cancer management from diagnosis to cure or palliation or to death, and this is a useful concept in the overview of cancer care services as a whole. Part of the role of oncologists affiliated to District General hIospitals must be to provide an on-site specialist service potentially accessible to all patients at any stage of their illness .
The benefits of cancer treatment are longer survival, relief of symptoms or both. Treatment may be unpleasant and costs must be taken into account (Rees, 1985; Markman, 1988) . Potentially curative and adjuvant therapies, if assessed as cost for each year of benefit obtained, are good value for money -generally less than £1000 per year per patient (Rees, 1991) . For example, taking into account all costs (chemotherapy, radiotherapy, hospital care, investigations etc) the average patient-benefit-year cost in advanced Hodgkin's Disease is approximately £450 and for adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) in localised breast cancer £400. Active palliative treatments, which are often relatively more expensive than 'best supportive care', need to be effective but must also use resources appropriately (Rubens, 1990 ) -long courses of radiotherapy or high cost or prolonged chemotherapy regimens (which are not part of an evaluated trial), particularly in-patient, usually achieve no better results than shorter, less expensive treatments (e.g. Price et al., 1986; Spiro & Souhami, 1990) . As a specific example a recent MRC prospective randomised trial showed that a two-treatment radiotherapy regimen was as safe, tolerable and effective as a more prolonged (10 fraction) treatment in palliating symptoms (MRC Lung Cancer Working Party, 1991 (Jaakkimainen et al., 1990) . Also, in non-specialist hands the approach to palliative anti-cancer treatment may be very nihilistic; 'more' may not be better but 'less' is sometimes inadequate. For example, continuous chemotherapy is better than intermittent chemotherapy for advanced breast cancer (Coates et al., 1987) . Dedicated oncologists should be available to advise in such situations and consensus guidelines for the management of common cancers established by expert panels (Timothy, 1988 (Slevin et al., 1990) . If palliation is the accepted aim, good quality of life becomes the top priority. However, in many clinical trials this has not been assessed and it is acknowledged that whereas quality of life is rarely improved by treatment that does not lead to tumour response, the latter may not correlate well with patient well-being. Quality of life as judged by patients themselves is different from that as assessed by their doctors and nurses (Slevin et al., 1988) . Nevertheless, physical function, mood, physical symptoms and social support are the key elements in assessment, and these should be monitored from diagnosis, through treatment and in 'terminal' illness (Mor, 1987) . In the latter phase the 'process' of care rather than the 'outcome' must be assessed and this is not straight-forward since care is more than usually multidisciplinary and specific measures to focus on the perception of the relatives rather than the person who is dying are also needed (NHS Management Executive, 1991) . Quality must be the endpoint however (Ahmedzai, 1990 ) and this should be assessed against the background of cost effectiveness and limited resources. Palliative care can be undertaken in hospital (including specialist cancer treatment centres), in hospices or at home. Most people would prefer to die at home (Dunlop et al., 1989 ) with a hospice as second choice; despite this about three quarters die in hospital, and proportionately few die in a hospice. Superficially, home care would appear to be a cheap option for the NHS but if the increased work load of the community team, the higher cost of community prescribing, the specialist care services required and the extra care and support needed for the patient's family are taken into account home care costs can be as high as those in institutions (Gray et al., 1987) . Hospice care represents excellent value to the NHS which provides overall less than half of the funding of hospices. Bed costs in hospices vary according to size but are probably about the same as those of an acute general hospital (Hill & Oliver, 1988 , Dunt et al., 1989 , which currently average about £110 per day (with the caveat that there are many variables in different settings; for example, this figure is likely to be higher in larger and specialist institutions). If in fact there is little to choose cost-wise between hospital, home and hospice, then in the ideal situation the choice of where to die should be made by the patients themselves, though inevitably any clinical decision will be affected by what is locally available.
Much work still needs to be done on consensus management, audit and quality assurance (Standing Medical Advisory Committee, 1990) in the field of palliation. Initiatives such as The Trent Region Palliative Care Centre should serve as development foci for all facets of the management of incurable disease and lead and stimulate effective research and teaching in this multidisciplinary field.
Oncologists and palliative care physicians, or hybrids of the two (McIllMurrary, 1987) , should lead the way and work together in initiating the new NHS changes to the future benefit of our patients (Hancock, in press ).
